🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

26 recruiting trials

for Non-Muscle Invasive Bladder Urothelial Carcinoma

Chemoablation for Low-Grade Bladder Cancer NCT07019220Phase 21 site📍 Vienna Ekaterina Laukhtina · Tests: Gemcitabine A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer NCT06503614Phase 25 sites📍 San Francisco📍 Tampa📍 New Brunswick John Sfakianos · Tests: Durvalumab, Monalizumab FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3 NCT05614739Phase 182 sites📍 Tucson📍 Duarte📍 Los Angeles Eli Lilly and Company · Tests: Vepugratinib, Pembrolizumab, enfortumab vedotin, Trastuzumab Deruxtecan, Midazolam A Randomized Trial of Bicalutamide in Non-Muscle Invasive Bladder Cancer NCT05521698Phase 16 sites📍 Tucson📍 Los Angeles📍 Bethesda University of Wisconsin, Madison · Tests: Bicalutamide, Biopsy Procedure, Biospecimen Collection, Questionnaire Administration, Transurethral Resection of Bladde… Is Prolonged Systemic Immunotherapy Necessary After Achieving Tumor-free Status in Patients With Extensive Transurethrally Unresectable Very-high-risk NMIBC? NCT07625527Phase 24 sites📍 Tianjin📍 Tianjin📍 Tianjin Tianjin Medical University Second Hospital · Tests: Active Surveillance, PD-1/PD-L1 Inhibitor-Based Systemic Immunotherapy Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC NCT07322263Phase 21 site📍 Iowa City Michael A. O'Donnell · Tests: Intravesical Gemcitabine and Docetaxel Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer NCT07480356Phase 311 sites📍 Queen Creek📍 Little Rock📍 Bakersfield Protara Therapeutics · Tests: TARA-002, Investigator's Choice of Intravesical Chemotherapy Irinotecan Liposomes Combined with Epirubicin in Recurrent Non-muscle Invasive Bladder Urothelium Carcinoma After Anthracyclines Treatment NCT06766266Phase 11 site📍 Chongqing First Affiliated Hospital of Chongqing Medical University · Tests: Irinotecan liposome II combination therapy regimen, Irinotecan liposome II combination therapy regimen Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC) NCT05037279Phase 36 sites📍 Vancouver📍 Kingston📍 Toronto Verity Pharmaceuticals Inc. · Tests: Bacillus Calmette-Guerin: Strain Russian BCG-I, Bacillus Calmette-Guerin: Strain TICE Increasing Pre-Surgical Identification of Muscle Invasive Tumor Evaluations Prior to Planned Cystectomy (INSITE) NCT06396533n/a2 sites📍 Omaha📍 Philadelphia Fox Chase Cancer Center A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors NCT05706129Phase 1, Phase 210 sites📍 Melbourne📍 Sydney📍 Clermont-Ferrand Lumara Bio Oncologics GmbH · Tests: [68Ga]Ga-DPI-4452, [177Lu]Lu-DPI-4452 Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309) NCT07566156Phase 326 sites📍 Little Rock📍 Santa Barbara📍 Aurora Astellas Pharma Global Development, Inc. · Tests: Enfortumab vedotin, Conventional Radiotherapy, Hypofractionated Radiotherapy, Cisplatin, Fluorouracil Comparison of CT and MR (VI-RADS) Imaging for Local Bladder Cancer Staging NCT07602010n/a1 site📍 Oslo Oslo University Hospital A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC NCT07725796Phase 115 sites📍 Queen Creek📍 Bakersfield📍 Murrieta UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd. · Tests: UGN-501 Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients NCT03945162Phase 216 sites📍 Chicago📍 Greenwood📍 Syracuse Theralase® Technologies Inc. · Tests: Ruvidar® (TLD-1433) bladder infusion and PDT Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer NCT07673016n/a23 sites📍 Oceanside📍 San Diego📍 San Jose Convergent Genomics, Inc. Phase I Study of Inactivated UPEC-FimON for Non Muscle Invasive Bladder Cancer After BCG or Intravesical Chemotherapy Failure NCT07881666Phase 13 sites📍 Kfar Saba📍 Jerusalem📍 Ramat Gan Hopec Pharma · Tests: Inactivated UPEC-FimON Vesical Imaging-Reporting and Data System (VI-RADS) Followed by Photodynamic Trans-urethral Resection of Bladder Tumours (PDD-TURBT) to Avoid Secondary Resections (Re-TURBT) in Non-Muscle Invasive Bladder Cancers (NMIBCs) NCT05962541Phase 41 site📍 Rome University of Roma La Sapienza · Tests: PDD-TURBT with hexaminolevulinate (Hexvix®), Power Led Saphira (TM) LCS103 Herbal Formula for Secondary Prevention of Non-Muscle Invasive Urothelial Carcinoma of the Bladder NCT07728474NA1 site📍 Haifa LifeBiotic Medical Research Ltd. · Tests: LCS103 Study on the Occurrence of Possible Relapses and on the Quality of Life in Patients Who Underwent TURBK. NCT06167356n/a1 site📍 Milan IRCCS San Raffaele Home-Based Physical Activity Program With Digital App Versus Health Education Group for Improving Physical Activity Among Patients With Non-muscle Invasive Bladder Cancer, The EMPOWER Trial NCT07302230NA1 site📍 Seattle University of Washington · Tests: Internet-Based Intervention, Best Practice, Internet-Based Intervention, Exercise Intervention, Health Telemonitoring DV+BCG in HER2-Expressing, BCG-Naïve High-Risk NMIBC NCT07207824Phase 31 site📍 Shanghai Fudan University · Tests: Active Comparator: BCG induction and maintenance, DV + BCG induction and maintenance Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial NCT06770582Phase 2147 sites📍 Tucson📍 Fayetteville📍 Rogers National Cancer Institute (NCI) · Tests: Biospecimen Collection, Cisplatin, Computed Tomography, Fluorouracil, Gemcitabine Pan-tumor MRD Study NCT06605404n/a47 sites📍 Birmingham📍 Bullhead City📍 Casa Grande Paradigm Health · Tests: blood and tissue samples, blood and tissue samples A Multicenter Prospective Cohort Study on Monitoring Recurrence of Urothelial Carcinoma Based on Detection of Urinary Microscopic Residual Disease (MRD) NCT06991868n/a1 site📍 Beijing Peking University First Hospital Prospective Sample Collection for Cancer of Bladder NCT03973671n/a1 site📍 Leuven Universitaire Ziekenhuizen KU Leuven
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy